• Triazole ALDH2 Activators Protect Against Cardiac I/R

  2026-09-21

  This 2025 ACS Medicinal Chemistry Letters study describes triazole-based aldehyde dehydrogenase 2 activators designed to improve activity and water solubility for myocardial ischemia-reperfusion injury. The lead compound Z17 activated ALDH2 strongly and improved cardiac function, infarct burden, and injury biomarkers in mice, while also illustrating how molecular simulation can guide optimization of allosteric cardioprotective agents.

• AI-10-49 and the inv(16) AML Bottleneck

  2026-09-20

  A mechanism-led perspective on how AI-10-49 disrupts CBFβ-SMMHC–RUNX1 signaling, connects target engagement with the MYCN/eIF4G1 survival axis, and strengthens translational acute myeloid leukemia research.

• Mdivi-1 and the ECM–Mitochondria Axis

  2026-09-19

  A translational framework for using Mdivi-1 to test how extracellular matrix remodeling, mitochondrial fission, apoptosis, and stress adaptation intersect across disease models.

• AI-10-49: An Assay-Ready CBFβ-SMMHC Inhibitor

  2026-09-18

  AI-10-49, a selective CBFβ-SMMHC inhibitor, provides a mechanistic way to connect RUNX1 release with chromatin, transcriptional, and leukemia phenotypes. This guide translates current inv(16) AML evidence into a rigorous assay and experimental-design framework.

• CSBTA Pharmacokinetics in MASH: Key Findings

  2026-09-18

  A 2025 study integrated plasma pharmacokinetics, tissue distribution, cellular accumulation, transporter assays, and metabolic-enzyme analysis to explain how MASH alters exposure to three major Corydalis saxicola Bunting total alkaloids. The results connect disease-state pharmacokinetic variability with CYP450, Oatp1b2, P-gp, and PXR-related changes, providing a mechanistic basis for dose-regimen optimization in MASLD/MASH research.

• Oral Colon Cancer Therapy with Dextran Microgels

  2026-09-17

  The reference study develops a sequential oral delivery platform in which microfluidized dextran microgels protect cisplatin/SPION lipid nanoparticles during gastrointestinal transit and release them in the colon. Dual targeting through dextran-mediated retention and folic-acid recognition enables combined chemotherapy and magnetothermal treatment in orthotopic colon cancer models while limiting nonspecific exposure.

• CCR7–Notch1 Crosstalk Drives Mammary Cancer Stemness

  2026-09-17

  Boyle et al. show that CCR7 signaling functionally intersects with Notch1 to sustain stem-like properties in MMTV-PyMT mammary cancer cells. The study uses complementary genetic, pharmacological, molecular, and cellular assays to support pathway crosstalk while highlighting why dual-axis validation is needed before therapeutic translation.

• Merimepodib (VX-497): Metabolic Antiviral Research

  2026-09-16

  Merimepodib (VX-497) is a selective IMPDH inhibitor that enables metabolism-informed antiviral, immunology, and cancer research. This article uses recent PEDV findings to show how cell context, nucleotide rescue, and orthogonal validation can improve experimental interpretation.

• Fingolimod (FTY720) in Immune-Cell Assays

  2026-09-16

  Fingolimod (FTY720) is more than an immunomodulatory agent for MS: it is a useful mechanistic comparator for separating S1P-dependent lymphocyte trafficking from engineered T-cell activation. This article explains how to interpret Fingolimod assays alongside the emerging magnetic CAR-T-mimicking platform without conflating pharmacological modulation with physical cell retargeting.

• Heparin Sodium as an HSPG Uptake Probe

  2026-09-15

  Heparin sodium is more than a benchmark glycosaminoglycan anticoagulant: it can help test whether heparan sulfate proteoglycans regulate nanovesicle uptake. This article connects coagulation assays with a recent Sertoli-cell nanovesicle study while defining the limits of that cross-domain interpretation.

• Cistanche Nanovesicles Rescue Sertoli-Cell Cell-Cycle Arrest

  2026-09-15

  This reference study identifies Cistanche deserticola-derived exosome-like nanovesicles as a potential intervention for cyclophosphamide-induced testicular injury. Its central mechanistic finding is that vesicle-delivered miR159b-3p suppresses P21 and restores CDK1-associated cell-cycle progression in Sertoli cells, while human non-obstructive azoospermia data provide translational context.

• Fluoxetine HCl Workflows for Motivation Research

  2026-09-14

  Fluoxetine HCl enables a connected workflow spanning serotonin transporter modulation, 5HT2C assays, neuronal plasticity, and reward-related behavior. This guide translates those capabilities into practical concentration planning, developmental-exposure designs, assay comparisons, and troubleshooting strategies for depression research.

• Fingolimod and In Vivo CAR-T-Mimicking Immunotherapy

  2026-09-14

  Fingolimod (FTY720) offers a mechanistic framework for studying lymphocyte trafficking, S1P signaling, and neuroimmune resilience alongside emerging in vivo CAR-T-mimicking platforms. This article translates those concepts into practical experimental strategy while distinguishing established evidence from forward-looking combination hypotheses.

• 10058-F4: From Myc Dimerization to TERT Assays

  2026-09-13

  Explore how 10058-F4, a c-Myc-Max dimerization inhibitor, can function as a mechanistic perturbation tool rather than merely a cytotoxicity reagent. This guide connects TERT chromatin regulation in human pluripotent stem cells with apoptosis assay design, AML research, and prostate cancer models.

• HotStart Universal 2X Green qPCR Master Mix Guide

  2026-09-12

  HotStart Universal 2X Green qPCR Master Mix combines hot-start Taq polymerase, Green I dye, and a universal ROX reference dye for dye-based quantitative PCR. It supports real-time PCR gene expression analysis, but melt curve analysis and appropriate controls remain necessary for specificity claims.

8451 records 1/564 page Next 12345 下5页 Last page